Get the Stockscreener App
3.45
5.74%
-0.21
Pre-market:
3.55
0.10
+2.90%
Terns Pharmaceuticals Inc stock is traded at $3.45, with a volume of 812.06K.
It is down -5.74% in the last 24 hours and down -15.44% over the past month.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.
See More
Previous Close:
$3.66
Open:
$3.65
24h Volume:
812.06K
Relative Volume:
0.62
Market Cap:
$293.04M
Revenue:
-
Net Income/Loss:
$-95.90M
P/E Ratio:
-2.6136
EPS:
-1.32
Net Cash Flow:
$-79.09M
1W Performance:
-4.96%
1M Performance:
-15.44%
6M Performance:
-61.47%
1Y Performance:
-51.27%
1-Day Range:
$3.435
$3.70
1-Week Range:
$3.24
$3.70
52-Week Range:
$3.24
$11.40
Terns Pharmaceuticals Inc Stock (TERN) Company Profile
Name
Terns Pharmaceuticals Inc
Sector
Industry
Phone
650-525-5535 EXT.101
Address
1065 EAST HILLSDALE BLVD., SUITE 100, FOSTER CITY
Compare TERN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TERN
Terns Pharmaceuticals Inc
|
3.45 | 293.04M | 0 | -95.90M | -79.09M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Terns Pharmaceuticals Inc Stock (TERN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-28-25 | Initiated | William Blair | Mkt Perform |
| Oct-31-24 | Initiated | Oppenheimer | Outperform |
| Jun-22-23 | Initiated | Mizuho | Buy |
| Jun-07-23 | Initiated | Jefferies | Buy |
| May-31-23 | Initiated | ROTH MKM | Buy |
| May-08-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-14-23 | Initiated | JMP Securities | Mkt Outperform |
| Feb-07-23 | Initiated | UBS | Buy |
| Sep-12-22 | Initiated | H.C. Wainwright | Neutral |
| Sep-14-21 | Resumed | Goldman | Buy |
| Mar-02-21 | Initiated | Cowen | Outperform |
| Mar-02-21 | Initiated | Goldman | Buy |
| Mar-02-21 | Initiated | JP Morgan | Overweight |
View All
Terns Pharmaceuticals Inc Stock (TERN) Latest News
Terns Pharmaceuticals’ SWOT analysis: promising pipeline drives stock potential - Investing.com
Terns Pharmaceuticals stock hits 52-week low at $3.27 - Investing.com India
Terns Pharmaceuticals stock hits 52-week low at $3.27 By Investing.com - Investing.com South Africa
This Weight Loss Stock Could Skyrocket by 462%, According to Wall Street - sharewise
Rhumbline Advisers Acquires 13,479 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
3 Growth Stocks with Exciting Potential - The Globe and Mail
Chronic Myeloid Leukemia Market Expected to Experience Major - openPR
Public market insider buying at Paramount Resources (POU) - The Globe and Mail
Terns Pharmaceuticals (TERN) Projected to Post Quarterly Earnings on Thursday - Defense World
Terns Pharmaceuticals stock hits 52-week low at $3.54 - Investing.com India
Terns Pharmaceuticals stock hits 52-week low at $3.54 By Investing.com - Investing.com South Africa
Brokerages Set Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Target Price at $18.30 - Defense World
William Blair Initiates Coverage on Terns Pharmaceuticals (NASDAQ:TERN) - Defense World
William Blair Initiates Terns Pharmaceuticals at Market Perform -February 28, 2025 at 08:12 am EST - Marketscreener.com
William Blair Initiates Coverage of Terns Pharmaceuticals (TERN) with Market Perform Recommendation - MSN
Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewswire
Terns Pharmaceuticals reports progress in clinical trials By Investing.com - Investing.com Australia
New Terns Pharmaceuticals CFO Receives $2.8M Stock Option Package: What's Behind the Compensation? - StockTitan
Terns Pharmaceuticals reports progress in clinical trials - Investing.com India
Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference - The Manila Times
Terns Pharmaceuticals Provides Program Updates and - GlobeNewswire
Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th ... - The Bakersfield Californian
Can Terns Pharmaceuticals' $372M Cash Runway Fuel Its Promising CML and Obesity Pipeline? - StockTitan
Terns Pharmaceuticals Names Andrew Gengos as Chief Financial Officer -February 25, 2025 at 04:55 am EST - Marketscreener.com
Terns Pharmaceuticals appoints Andrew Gengos as CFO - TipRanks
Terns Pharmaceuticals Appoints Andrew Gengos as CFO - MSN
Terns Pharmaceuticals appoints new CFO to bolster growth By Investing.com - Investing.com Nigeria
Terns Pharmaceuticals appoints new CFO to bolster growth - Investing.com India
Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer - The Manila Times
Can This Former Amgen VP Transform Terns Pharmaceuticals as New CFO? - StockTitan
Terns Pharmaceuticals stock hits 52-week low at $4 - Investing.com India
Terns Pharmaceuticals stock hits 52-week low at $4 By Investing.com - Investing.com Nigeria
Oppenheimer Initiates Coverage of Terns Pharmaceuticals (TERN) with Outperform Recommendation - MSN
Terns Pharmaceuticals Appoints Robert Azelby to Board - TipRanks
Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors - GlobeNewswire
Can This New Board Addition Transform Terns' Oncology Commercialization Strategy? - StockTitan
Savant Capital LLC Makes New $89,000 Investment in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Terns Pharmaceuticals stock hits 52-week low at $4.16 - MSN
Terns Pharmaceuticals stock hits 52-week low at $4.16 By Investing.com - Investing.com Canada
Bleakley Financial Group LLC Boosts Stock Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Terns Pharmaceuticals announces CFO transition and consulting agreement - MSN
Terns Pharmaceuticals Inc Stock (TERN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):